Safe Haven Investment Portfolio Stocks: Palatin Technologies, Inc. (NYSE:PTN), Hologic, Inc. (NASDAQ:HOLX)

Shares of Palatin Technologies, Inc. (NYSE:PTN) [Trend Analysis] runs in leading trade, it plunging -31.43% to traded at $0.56. The firm has price volatility of 20.98% for a week and 13.73% for a month. Its beta stands at 1.61 times. . Narrow down four to firm performance, its weekly performance was -4.24% and monthly performance was 15.65%.

Palatin Technologies, Inc. (NYSEMKT:PTN) reported that pricing of an underwritten public offering of 25,384,616 shares of its ordinary stock and warrants to purchase 12,692,310 shares of its ordinary stock for anticipated gross proceeds of $16.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Palatin.  The shares of ordinary stock and warrants will be provided as Series A Units, with each Series A Unit consisting of one share of ordinary stock and a Series J warrant to purchase 0.50 of a share of ordinary stock, and will be priced at $0.65 per unit.

The co is presenting price to cash flow as 5.87, the low single digit may indicate stock is undervalued and vise versa. On other hand, keeping in mind stable cash flows but few growth prospects make traders to value lower. The firm has price volatility of 20.98% for a week and 13.73% for a month. Its beta stands at 1.61 times. Narrow down four to firm performance, its weekly performance was -4.24% and monthly performance was 15.65%.

Hologic, Inc. (NASDAQ:HOLX) runs in leading trade, it felling down to knees -1.67% to traded at $37.64. HOLX attains analyst recommendation of 2.00 on scale of 1-5 with week’s performance of -3.41%.

To find out the technical position of HOLX, it holds price to book ratio of 4.88 that unearth high-growth companies selling at low-growth prices, but it requires appropriate measurement approach. It has forward price to earnings ratio of 15.95, and price to earnings ratio calculated as 32.53. The price to earnings growth ration calculated as 3.34. HOLX is presenting price to cash flow of 19.10 and free cash flow concluded as 15.21.

EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 154.30%, and looking further price to next year’s EPS is 9.87%. While take a short look on price to sales ratio, that was 3.70 and price to earning ration of 32.53 attracting passive investors.

 

About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *